TY - JOUR
T1 - Platelet aggregability after endoscopic intravariceal injection of 5 per cent ethanolamine oleate into oesophageal varices
AU - Yamaga, H.
AU - Hashizume, M.
AU - Kitano, S.
AU - Higashi, H.
AU - Sugimachi, K.
PY - 1989/9
Y1 - 1989/9
N2 - Platelet aggregability and the coagulative and fibrinolytic systems were examined in 45 patients who underwent endoscopic injection sclerotherapy for oesophageal varices. Five per cent ethanolamine oleate, the sclerosant used, was injected into the oesophageal varices. There were significant increases in the concentrations of fibrinopeptide A, fibrinopeptide B‐β‐15–42 and fibrin degradation products‐E after the sclerotherapy. At 1 h after the sclerotherapy the mean(s.e.m.) platelet aggregation was significantly suppressed to 71·9(4·2) per cent of that before the treatment (P <0·01). There was a gradual recovery within 1 week to the same level seen before the sclerotherapy. Thomboxane B2 and 6‐keto‐prostaglandin F1α, both stable products of thromboxane A2 and prostacyclin respectively, showed significant temporary increases after the sclerotherapy (P <0·01). The peak increase in the level of thromboxane B2 was noted within 1 h after the sclerotherapy and earlier than that for 6‐keto‐prostaglandin F1α. This increased ratio of prostacyclin and thromboxane A2 may be related to the marked limitation in platelet aggregation.
AB - Platelet aggregability and the coagulative and fibrinolytic systems were examined in 45 patients who underwent endoscopic injection sclerotherapy for oesophageal varices. Five per cent ethanolamine oleate, the sclerosant used, was injected into the oesophageal varices. There were significant increases in the concentrations of fibrinopeptide A, fibrinopeptide B‐β‐15–42 and fibrin degradation products‐E after the sclerotherapy. At 1 h after the sclerotherapy the mean(s.e.m.) platelet aggregation was significantly suppressed to 71·9(4·2) per cent of that before the treatment (P <0·01). There was a gradual recovery within 1 week to the same level seen before the sclerotherapy. Thomboxane B2 and 6‐keto‐prostaglandin F1α, both stable products of thromboxane A2 and prostacyclin respectively, showed significant temporary increases after the sclerotherapy (P <0·01). The peak increase in the level of thromboxane B2 was noted within 1 h after the sclerotherapy and earlier than that for 6‐keto‐prostaglandin F1α. This increased ratio of prostacyclin and thromboxane A2 may be related to the marked limitation in platelet aggregation.
UR - http://www.scopus.com/inward/record.url?scp=0024430049&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0024430049&partnerID=8YFLogxK
U2 - 10.1002/bjs.1800760922
DO - 10.1002/bjs.1800760922
M3 - Article
C2 - 2804591
AN - SCOPUS:0024430049
SN - 0007-1323
VL - 76
SP - 939
EP - 942
JO - British Journal of Surgery
JF - British Journal of Surgery
IS - 9
ER -